Omeros, a Seattle-based drug discovery firm, is getting an injection of money from Washington State's Life Sciences Discovery Fund and local entrepreneur and billionaire Paul Allen, Xconomy reports. Omeros is trying to come up with therapeutics that bind G-protein coupled receptors — targets that have been deemed "undruggable" by many.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.